Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 12/20 | 0.65 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485847 | 0.85 | F2R (0.69) | F2RFKBP1AAKR1C3MAPTSMN1; SMN2 | |
| SCHEMBL3793030 | 0.83 | F2R (0.66) | F2RFKBP1AAKR1C3MAPTSMN1; SMN2 | |
| SCHEMBL640569 | 0.83 | F2R (0.66) | F2RFKBP1AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL643116 | 0.83 | F2R (0.66) | F2RFKBP1AAKR1C3MAPTSMN1; SMN2 | |
| SCHEMBL485754 | 0.82 | F2R (0.71) | F2RFKBP1AAKR1C3MAPTSMN1; SMN2 | |
| SCHEMBL641244 | 0.82 | F2R (0.65) | F2RFKBP1AAKR1C3MAPTSMN1; SMN2 | |
| SCHEMBL9888673 | 0.82 | F2R (0.63) | F2RAKR1C3 | |
| SCHEMBL640992 | 0.81 | F2R (0.73) | F2RFKBP1AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL1581192 | 0.81 | F2R (0.77) | F2RFKBP1AAKR1C3MAPTSMN1; SMN2 | |
| SCHEMBL16579598 | 0.81 | F2R (0.81) | F2RFKBP1AMAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142690-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142690-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010136137-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136137-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142690-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1339/4885FKBP1A 1413/4885AKR1C3 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.